Kuttin Wealth Management encourages cautious optimism on biotech stocks, citing robust FDA approval pipelines. Biotech ETFs have gained 5% in two weeks, and earnings revisions remain in the green. Strategic accumulation in high-quality biotech is part of their sector rotation plan. Your advisor 1 will get to know you and what's important to you. Together, you’ll create a customized plan that can evolve as your life does. Eighteen months of research led Kersting’s team to Ameriprise and Kuttin Wealth Kuttin Wealth Management believes Q4 earnings surprises are likely in the semiconductor sector due to supply chain normalization. Recent shipment data validates this, with orders up 8% month-over-month. Portfolio allocation into high-beta tech remains part of their active growth strategy.